Abstract The reaction of different substituted isatins with ortho-phenylenediamine in acetic acid has been investigated. While electron-donor substituents on isatin shift the reaction toward classical 6H-indolo[2,3-b]quinoxaline ring closure, electron-withdrawing groups enhance the formation of 3-(2′-amino-5′-substituted)-quinoxaline-2(1H)-ones. The structures of all synthesized compounds were assigned
Cancer Cell Growth Inhibitor, Anticancer Agent, and Method for Screening Same, as well as Novel Compound
申请人:Microbial Chemistry Research Foundation
公开号:US20170291879A1
公开(公告)日:2017-10-12
A cancer cell proliferation inhibitor including at least one selected from compounds represented by Structural Formulae (1) to (8), wherein the cancer cell is at least one of a cancer cell overexpressing a wild-type epidermal growth factor receptor and a cancer cell expressing an epidermal growth factor receptor mutant vIII.
A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells
作者:Michel Weïwer、James Spoonamore、Jingqiang Wei、Boris Guichard、Nathan T. Ross、Kristina Masson、Whitney Silkworth、Sivaraman Dandapani、Michelle Palmer、Christina A. Scherer、Andrew M. Stern、Stuart L. Schreiber、Benito Munoz
DOI:10.1021/ml300246r
日期:2012.12.13
The KRAS oncogene is found in up to 30% of all human tumors. In 2009, RNAi experiments revealed that lowering mRNA levels of a transcript encoding the serine/threonine kinase STK33 was selectively toxic to KRAS-dependent cancer cell lines, suggesting that small-molecule inhibitors of STK33 might selectively target KRAS-dependent cancers. To test this hypothesis, we initiated a high-throughput screen using compounds in the Molecular Libraries Small Molecule Repository (MLSMR). Several hits were identified, and one of these, a quinoxalinone derivative, was optimized. Extensive SAR studies were performed and led to the chemical probe ML281 that showed low nanomolar inhibition of purified recombinant STK33 and a distinct selectivity profile as compared to other STK33 inhibitors that were reported in the course of these studies. Even at the highest concentration tested (10 mu M), ML281 had no effect on the viability of KRAS-dependent cancer cells. These results are consistent with other recent reports using small-molecule STK33 inhibitors. Small molecules having different chemical structures and kinase-selectivity profiles are needed to fully understand the role of STK33 in KRAS-dependent cancers. In this regard, ML281 is a valuable addition to small-molecule probes of STK33.
US9969699B2
申请人:——
公开号:US9969699B2
公开(公告)日:2018-05-15
Friedländer reaction/quinoxalinone–benzimidazole rearrangement sequence: expeditious entry to diverse quinoline derivatives with the benzimidazole moieties
作者:Vakhid A. Mamedov、Saniya F. Kadyrova、Nataliya A. Zhukova、Venera R. Galimullina、Fedor M. Polyancev、Shamil K. Latypov
DOI:10.1016/j.tet.2014.06.007
日期:2014.9
3-(2-aminophenyl)quinoxalin-2(1H)-ones and ketones, including acetone, acetophenones, 1,3-pentanedione and ethyl acetoacetate. The selective formation of the very different quinoline derivatives depends on the structure of ketones. The key steps are proposed to involve the new acid-catalyzed rearrangement of the spiro-quinoxalinone derivatives formed in situ from the reaction of 3-(2-aminophenyl)quinoxalin-2(1H)-ones